Inventiva: Acceleration Of The Clinical Development Activities And Consolidation Of The Financial Position In 2016
Daix (France), March 27, 2017 – 7:30 am CET - Inventiva, a biopharmaceutical company developing innovative therapies, particularly to treat fibrosis, provides a business update and reports its financial results for the year ended December 31, 2016.
Main highlights and business overview
• Launch of the Phase IIb trial investigating IVA337 in NASH
• Patient recruitment for IVA337 Phase IIb trial in systemic sclerosis in line with the timetable announced
• Phase I/II clinical trial investigating IVA336 in Maroteaux-Lamy syndrome (MPS VI) in preparation
• Publication of the US patent covering the use of IVA336 for the treatment of MPS VI patients
• Initiation of ABBV-553 Phase I trial, the first clinical candidate resulting from the partnership with AbbVie
• New partnership agreement with Boehringer Ingelheim to develop new treatments for idiopathic pulmonary fibrosis
Key financial information
• Successful IPO on Euronext Paris with €48.5m raised on February 15th 2017
• Cash position as of December 31st 2016 and before taking into account the IPO proceeds, of €24.8m, an increase of €2.3m compared with 2015
• Sales of €9.4m, an increase of 94% compared to 2015
Key newsflow and expected milestones
2017
• End of recruitment for the two Phase IIb trials in systemic sclerosis and NASH
• Recruitment of the first patient for the Phase I/II trial in MPS VI
• Milestone payments from the partnerships with AbbVie and Boehringer Ingelheim 2018
• Results of IVA337 Phase IIb trial in NASH
• Results of IVA337 Phase IIb trial in systemic sclerosis
• Results of IVA336 Phase I/II trial in MPS VI
Frédéric Cren, CEO and co-founder of Inventiva, said: “Our successful IPO on Euronext Paris – one of the largest in the sector with over €48 million raised – comes after an excellent 2016. The IPO proceeds strengthen an already positive cash position and will enable us to finance the development of our project portfolio.”
For full access, please click here.
Main highlights and business overview
• Launch of the Phase IIb trial investigating IVA337 in NASH
• Patient recruitment for IVA337 Phase IIb trial in systemic sclerosis in line with the timetable announced
• Phase I/II clinical trial investigating IVA336 in Maroteaux-Lamy syndrome (MPS VI) in preparation
• Publication of the US patent covering the use of IVA336 for the treatment of MPS VI patients
• Initiation of ABBV-553 Phase I trial, the first clinical candidate resulting from the partnership with AbbVie
• New partnership agreement with Boehringer Ingelheim to develop new treatments for idiopathic pulmonary fibrosis
Key financial information
• Successful IPO on Euronext Paris with €48.5m raised on February 15th 2017
• Cash position as of December 31st 2016 and before taking into account the IPO proceeds, of €24.8m, an increase of €2.3m compared with 2015
• Sales of €9.4m, an increase of 94% compared to 2015
Key newsflow and expected milestones
2017
• End of recruitment for the two Phase IIb trials in systemic sclerosis and NASH
• Recruitment of the first patient for the Phase I/II trial in MPS VI
• Milestone payments from the partnerships with AbbVie and Boehringer Ingelheim 2018
• Results of IVA337 Phase IIb trial in NASH
• Results of IVA337 Phase IIb trial in systemic sclerosis
• Results of IVA336 Phase I/II trial in MPS VI
Frédéric Cren, CEO and co-founder of Inventiva, said: “Our successful IPO on Euronext Paris – one of the largest in the sector with over €48 million raised – comes after an excellent 2016. The IPO proceeds strengthen an already positive cash position and will enable us to finance the development of our project portfolio.”
For full access, please click here.